The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

PSC-IBD Coexistence

Concomitant primary sclerosing cholangitis and inflammatory bowel disease as a distinct clinical entity.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Dahiliye (İç Hastalıkları) department. Book Appointment →

What is PSC-IBD Coexistence?

PSC-IBD denotes the simultaneous presence of primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD); 60–80% of PSC patients have concomitant IBD, predominantly ulcerative colitis.

Epidemiology: PSC affects approximately 1/100,000, with a male predominance (2:1) and median age at diagnosis of 30–40 years; PSC develops in 2–8% of IBD patients.

Pathophysiology: shared autoimmune-mediated inflammation, gut-liver axis dysregulation, microbiota changes and aberrant lymphocyte trafficking via the MAdCAM-1/α4β7 axis are implicated.

PSC-IBD has a distinct phenotype: pancolitis with right-sided predominance, rectal sparing, backwash ileitis and quiescent or mild colitis activity but markedly elevated colorectal dysplasia/cancer risk.

Symptoms

Fatigue, pruritus, jaundice and right-upper-quadrant discomfort (PSC-related)
Chronic diarrhea, hematochezia, abdominal pain and tenesmus (IBD-related)
Weight loss, low-grade fever and night sweats
Often asymptomatic at PSC diagnosis; abnormal liver tests on routine screening
Cholangitis episodes: fever, jaundice and right-upper-quadrant pain
Hepatosplenomegaly and signs of portal hypertension in advanced disease
Extraintestinal manifestations: arthralgia, uveitis, erythema nodosum and pyoderma gangrenosum
Symptoms suggestive of cholangiocarcinoma: progressive jaundice, weight loss and worsening pruritus

Risk Factors

Diagnosis of inflammatory bowel disease, particularly ulcerative colitis (5–7% develop PSC)
Male sex (2:1 male-to-female ratio in PSC)
HLA-B8, HLA-DR3 and HLA-DRB1*1301 alleles (genetic susceptibility)
Family history of PSC, IBD or autoimmune disease
Age 30–40 years at IBD diagnosis
Smoking is paradoxically protective against PSC (unlike Crohn disease)
Northern European or North American ethnic background
Long-standing IBD with extensive colonic involvement

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Persistently elevated cholestatic liver enzymes (ALP, GGT) in any patient with IBD
  • New-onset jaundice, severe pruritus or right-upper-quadrant pain
  • Recurrent cholangitis episodes (fever, jaundice, biliary pain)
  • New abdominal pain or significant weight loss in established PSC-IBD
  • Worsening colitis symptoms despite optimized therapy
  • Surveillance colonoscopy and MRCP intervals (annual recommended)
  • Symptoms suggesting cholangiocarcinoma or colorectal cancer
  • Pre-transplant evaluation in advanced PSC

Treatment Methods

01
Diagnostic workup: cholestatic liver tests (ALP, GGT), MRCP showing multifocal biliary strictures and beading; liver biopsy reserved for small-duct PSC suspicion
02
IBD evaluation: full colonoscopy with multiple biopsies (right colon predominance, microscopic colitis frequent); fecal calprotectin to monitor activity
03
PSC-specific therapy: ursodeoxycholic acid 13–15 mg/kg/day improves liver tests but does not change disease progression; high-dose UDCA (>28 mg/kg/day) is contraindicated due to harm
04
IBD therapy: 5-ASA agents (mesalazine 2.4–4.8 g/day) for mild colitis, possibly with chemopreventive benefit; thiopurines, vedolizumab and ustekinumab for moderate-severe disease
05
Anti-TNF agents (infliximab, adalimumab) for refractory IBD; vedolizumab is preferred in PSC-IBD due to gut-selective action and favorable safety
06
Cholangitis management: broad-spectrum antibiotics (ciprofloxacin plus metronidazole, or piperacillin-tazobactam) for acute episodes; prophylactic antibiotics for recurrent cholangitis
07
Endoscopic therapy: ERCP with balloon dilation for dominant strictures; routine stenting is avoided due to infection risk
08
Cholangiocarcinoma surveillance: annual MRI/MRCP plus CA 19-9 measurement; ERCP with brush cytology for suspicious strictures; FISH analysis to enhance sensitivity
09
Colorectal cancer surveillance: annual surveillance colonoscopy starting at PSC diagnosis (5-fold increased risk versus IBD alone); high-definition chromoendoscopy preferred
10
Pruritus management: cholestyramine 4 g 1–4 times daily, rifampin 150–300 mg twice daily, naltrexone 50 mg daily, or sertraline; adjunctive ursodeoxycholic acid for hepatic itch
11
Nutritional management: fat-soluble vitamin replacement (A, D, E, K), calcium and vitamin D for osteoporosis prevention
12
Liver transplantation: indicated for end-stage liver disease, refractory pruritus, recurrent cholangitis or early cholangiocarcinoma; PSC recurs in 20–25% of transplanted grafts
13
Post-transplant management: continued IBD surveillance and treatment; calcineurin inhibitor immunosuppression (tacrolimus preferred over cyclosporine)
14
Colectomy considerations: total proctocolectomy for high-grade dysplasia, cancer or refractory colitis; ileal pouch-anal anastomosis acceptable, with monitoring for pouchitis
15
Multidisciplinary follow-up: hepatology, gastroenterology, colorectal surgery and transplant teams; quarterly liver tests, annual imaging and endoscopy
16
Prognosis: median transplant-free survival 14–21 years from PSC diagnosis; cholangiocarcinoma develops in 10–20% over time; 5–10% lifetime colorectal cancer risk

Which Department to Visit?

You can visit our Dahiliye (İç Hastalıkları) department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Dahiliye (İç Hastalıkları) Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.